Psilocybin Mushrooms

Overview

Psilocybin mushrooms contain the classic psychedelic psilocybin, which is converted to psilocin after ingestion. The current wiki evidence presents them in three distinct settings: sacramental access through Psychedelic Churches, measured longevity self-experimentation, and controlled psychiatric research using dose-standardized synthetic psilocybin.

Current Profile

The religious-access source treats mushrooms as the central sacrament at Zydor Church, where theology, high-dose practice, donation-based access, local decriminalization, and unresolved federal controlled-substance law coexist. The Bryan Johnson source adds a measured self-experiment branch in which three reported 25 mg sessions were associated with changes in brain and metabolic measurements, but the episode does not establish causal or generalizable benefit.

The Huberman psilocybin episode adds a clinical-mechanism branch. It describes psilocybin as a tryptamine whose active metabolite strongly engages serotonin 2A receptors and may temporarily reduce brain-network hierarchy while increasing cross-region communication. Therapeutic interpretation remains conditional: mushroom potency varies, controlled trials generally use synthetic material, and any benefit is attributed to a combined Psychedelic Therapy Mechanism involving selection, dose, set and setting, guides, music, psychotherapy, and Psychedelic Integration rather than to the molecule alone.

The Matthew Johnson Essentials edit reinforces the clinical-versus-casual distinction with a protocol using pure measured psilocybin, psychiatric and cardiovascular screening, rapport, supportive setting, and monitoring. Its high-dose depression, addiction, and cancer-distress signals remain source-scoped because the summary supplies neither full trial methods nor an individualized risk model.

Key Characteristics

• Contains psilocybin, which is converted to psychoactive psilocin and is described as acting primarily through serotonin 2A receptors.
• Natural mushroom potency varies by strain, batch, age, and storage, making mushroom weight an unreliable substitute for controlled synthetic dosing.
• Can produce visual changes, synesthesia, altered self-boundaries, connectedness, anxiety, and marked changes in cognition and perception.
• Has religious, self-experimental, and clinical-research uses whose evidence, legal status, safeguards, and goals should not be conflated.
• Depression and addiction findings are promising but depend on condition, selection, protocol, dose, adverse events, support, and follow-up.
• Psychosis or bipolar vulnerability, age, pregnancy, breastfeeding, serotonergic medication, cardiovascular response, and setting are explicit risk considerations.

Evidence

• Sacramental access - A trip to the magic mushroom megachurch describes multiple mushroom forms and potencies at Zydor while keeping federal-law and liability risk visible.
• Measured self-experimentation - Bryan Johnson: I Just Took the Most Powerful Dose of DMT in the World… Here’s What It Was Like records Johnson’s reported psilocybin doses and apparent measurement changes while preserving single-subject uncertainty.
• Pharmacology and variability - How Psilocybin Can Rewire Our Brain, Its Therapeutic Benefits & Its Risks connects psilocin, serotonin 2A activity, variable mushroom potency, and synthetic clinical dosing.
• Clinical context - How Psilocybin Can Rewire Our Brain, Its Therapeutic Benefits & Its Risks pairs depression signals with preparation, supported setting, music, guides, psychotherapy, integration, adverse events, and contraindications.
• Measured-session corroboration - Essentials: Psychedelics for Treating Mental Disorders | Dr. Matthew Johnson pairs pure measured psilocybin with psychiatric and cardiovascular screening, rapport, supportive setting, monitoring, and explicit bad-trip risk.

Qualifications

This page does not equate sacramental access, personal self-experimentation, and controlled clinical research. The sources do not establish a safe mushroom dose, individual eligibility, universal benefit, current legality, or a self-treatment protocol. The Johnson Essentials edit overlaps the longer interview represented elsewhere in the wiki and is not independent replication. Potency, product identity, psychiatric history, other medicines, physical setting, professional conduct, and emergency support materially affect risk.

What Changed

• The Essentials edit reinforces measured-product, screening, setting, and bad-trip boundaries without changing the existing clinical profile.

Relationships

• Psychedelic Therapy Mechanism - explains why receptor action alone does not determine therapeutic outcome.
• Psychedelic Clinical Supervision Boundary - supplies screening, oversight, legal, and follow-up constraints.
• Neuroplasticity / 神经可塑性 - candidate change process that is not automatically adaptive or beneficial.
• Psychedelic Integration - translates an acute experience into tested ordinary-life learning.
• Zydor Church - religious-access setting in the Planet Money source.
• Controlled Substances Act - federal legal-risk context in the church source.
• Default Mode Network - network interpretation used in the Johnson self-experiment source.